Neurosurgical convection-enhanced delivery of treatments for Parkinson's disease

Journal of Clinical Neuroscience

Volumn 18, Issue 9, 2011, Pages 1163-1167

  Lam, Miu Fei ^a,b   Thomas, Meghan G ^b,c   Lind, Christopher R P ^a,b  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c EDITH COWAN UNIVERSITY   (Australia)

Author keywords

Convection; Drug delivery systems; Infusions; Intralesional; Neurosurgical procedures; Parkinson's disease

Indexed keywords

CERE 120; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE DECARBOXYLASE; NEURTURIN; UNCLASSIFIED DRUG;

BRAIN CIRCULATION; BRAIN TOXICITY; CATHETER; CENTRAL NERVOUS SYSTEM; COMPUTER ASSISTED SURGERY; CONVECTION ENHANCED DELIVERY; CORPUS STRIATUM; DIFFUSION TENSOR IMAGING; EQUIPMENT DESIGN; HUMAN; LABORATORY TEST; NEUROPROTECTION; NEUROSURGERY; NONHUMAN; PARENCHYMA; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STEREOTAXIC SURGERY; TREATMENT FAILURE;

ANTIPARKINSON AGENTS; CATHETERS, INDWELLING; CONVECTION; CORPUS STRIATUM; DRUG DELIVERY SYSTEMS; HUMANS; PARKINSON DISEASE;

EID: 79961013057     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2011.01.012     Document Type: Review

References (62)

1. Bobo RH, Laske DW, Akbasak A, et al. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994;91:2076-80. (Pubitemid 24092045)
2. Rogawski MA. Convection-enhanced delivery in the treatment of epilepsy. Neurotherapeutics 2009;6:344-51.
3. Sampson JH, Archer G, Pedain C, et al. Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg 2010;113:301-9.
4. Morrison PF, Lonser RR, Oldfield EH. Convective delivery of glial cell line-derived neurotrophic factor in the human putamen. J Neurosurg 2007;107:74-83. (Pubitemid 47026475)
5. Salvatore MF, Ai Y, Fischer B, et al. Point source concentration of GDNF may explain failure of phase II clinical trial. Exp Neurol 2006;202:497-505.
6. Fiandaca MS, Forsayeth JR, Dickinson PJ, et al. Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics 2008;5:123-7. (Pubitemid 350299297)
7. Oh S, Odland R, Wilson SR, et al. Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. J Neurosurg 2007;107:568-77. (Pubitemid 47451041)
8. Raghavan R, Brady ML, Rodriguez-Ponce MI, et al. Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurg Focus 2006;20:E12.
9. Krauze MT, Saito R, Noble C, et al. Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg 2005;103:923-9. (Pubitemid 43194589)
10. Hall WA. Convection-enhanced delivery: neurosurgical issues. Curr Drug Targets 2009;10:126-30.
11. Yin D, Forsayeth J, Bankiewicz KS. Optimized cannula design and placement for convection-enhanced delivery in rat striatum. J Neurosci Methods 2010;187:46-51.
12. Hadaczek P, Yamashita Y, Mirek H, et al. The "perivascular pump" driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Mol Ther 2006;14:69-78.
13. Larson PS, Richardson RM, Starr PA, et al. Magnetic resonance imaging of implanted deep brain stimulators: experience in a large series. Stereotact Funct Neurosurg 2008;86:92-100. (Pubitemid 351341535)
14. Starr PA, Martin AJ, Ostrem JL, et al. Subthalamic nucleus deep brain stimulator placement using high-field interventional magnetic resonance imaging and a skull-mounted aiming device: technique and application accuracy. J Neurosurg 2010;112:479-90.
15. Patel NK, Plaha P, Gill SS. Magnetic resonance imaging-directed method for functional neurosurgery using implantable guide tubes. Neurosurgery 2007;61:358-65 discussion 65-6.
16. Sampson JH, Raghavan R, Brady ML, et al. Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro Oncol 2007;9:343-53. (Pubitemid 47179574)
17. Krauze MT, McKnight TR, Yamashita Y, et al. Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. Brain Res Brain Res Protoc 2005;16:20-6. (Pubitemid 41774067)
18. Krauze MT, Forsayeth J, Park JW, et al. Real-time imaging and quantification of brain delivery of liposomes. Pharm Res 2006;23:2493-504. (Pubitemid 44691597)
19. Szerlip NJ, Walbridge S, Yang L, et al. Real-time imaging of convection-enhanced delivery of viruses and virus-sized particles. J Neurosurg 2007;107:560-7. (Pubitemid 47451040)
20. Su X, Kells AP, Aguilar Salegio EA, et al. Real-time MR imaging with gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors. Mol Ther 2010;18:1490-5.
21. Chen ZJ, Gillies GT, Broaddus WC, et al. A realistic brain tissue phantom for intraparenchymal infusion studies. J Neurosurg 2004;101:314-22. (Pubitemid 38971010)
22. Vogelbaum MA. Convection enhanced delivery for the treatment of malignant gliomas: symposium review. J Neurooncol 2005;73:57-69. (Pubitemid 40823269)
23. Krauze MT, Saito R, Noble C, et al. Effects of the perivascular space on convection-enhanced delivery of liposomes in primate putamen. Exp Neurol 2005;196:104-11. (Pubitemid 41416652)
24. Mamot C, Nguyen JB, Pourdehnad M, et al. Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J Neurooncol 2004;68:1-9. (Pubitemid 39137344)
25. MacKay JA, Deen DF, Szoka Jr FC. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Brain Res 2005;1035:139-53. (Pubitemid 40250186)
26. Hamilton JF, Morrison PF, Chen MY, et al. Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin. Exp Neurol 2001;168:155-61. (Pubitemid 32195267)
27. Kroll RA, Pagel MA, Muldoon LL, et al. Increasing volume of distribution to the brain with interstitial infusion: dose, rather than convection, might be the most important factor. Neurosurgery 1996;38:746-52 discussion 52-4.
28. Hadaczek P, Mirek H, Bringas J, et al. Basic fibroblast growth factor enhances transduction, distribution, and axonal transport of adeno-associated virus type 2 vector in rat brain. Hum Gene Ther 2004;15:469-79. (Pubitemid 38639618)
29. Mastakov MY, Baer K, Xu R, et al. Combined injection of rAAV with mannitol enhances gene expression in the rat brain. Mol Ther 2001;3:225-32. (Pubitemid 32509825)
30. Regino CA, Walbridge S, Bernardo M, et al. A dual CT-MR dendrimer contrast agent as a surrogate marker for convection-enhanced delivery of intracerebral macromolecular therapeutic agents. Contrast Media Mol Imaging 2008;3:2-8. (Pubitemid 351493973)
31. Allard E, Passirani C, Benoit JP. Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials 2009;30:2302-18.
32. Perlstein B, Ram Z, Daniels D, et al. Convection-enhanced delivery of maghemite nanoparticles: increased efficacy and MRI monitoring. Neuro Oncol 2008;10:153-61.
33. Voges J, Reszka R, Gossmann A, et al. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol 2003;54:479-87. (Pubitemid 37176543)
34. Bankiewicz KS, Eberling JL, Kohutnicka M, et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 2000;164:2-14. (Pubitemid 30490717)
35. Kim J, Yoon YS, Lee H, et al. AAV-GAD gene for rat models of neuropathic pain and Parkinson's disease. Acta Neurochir Suppl 2008;101:99-105.
36. Mandel RJ, Spratt SK, Snyder RO, et al. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci USA 1997;94:14083-8.
37. Marks Jr WJ, Ostrem JL, Verhagen L, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 2008;7:400-8.
38. Peltekian E, Parrish E, Bouchard C, et al. Adenovirus-mediated gene transfer to the brain: methodological assessment. J Neurosci Methods 1997;71:77-84. (Pubitemid 27145774)
39. Bilang-Bleuel A, Revah F, Colin P, et al. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc Natl Acad Sci USA 1997;94:8818-23.
40. Kordower JH, Herzog CD, Dass B, et al. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol 2006;60:706-15. (Pubitemid 46048488)
41. Johnston LC, Eberling J, Pivirotto P, et al. Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. Hum Gene Ther 2009;20:497-510.
42. Lin LF, Doherty DH, Lile JD, et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993;260:1130-2. (Pubitemid 23186789)
43. Hou JG, Lin LF, Mytilineou C. Glial cell line-derived neurotrophic factor exerts neurotrophic effects on dopaminergic neurons in vitro and promotes their survival and regrowth after damage by 1-methyl-4-phenylpyridinium. J Neurochem 1996;66:74-82. (Pubitemid 26010766)
44. Eberling JL, Kells AP, Pivirotto P, et al. Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys. Hum Gene Ther 2009;20:511-8.
45. Eslamboli A, Georgievska B, Ridley RM, et al. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J Neurosci 2005;25:769-77. (Pubitemid 40170991)
46. Gash DM, Zhang Z, Ovadia A, et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996;380:252-5. (Pubitemid 26090648)
47. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003;9:589-95. (Pubitemid 36597106)
48. Slevin JT, Gerhardt GA, Smith CD, et al. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 2005;102:216-22. (Pubitemid 43194069)
49. Slevin JT, Gash DM, Smith CD, et al. Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year each of treatment and withdrawal. Neurosurg Focus 2006;20:E1.
50. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006;59:459-66. (Pubitemid 43358066)
51. Hadaczek P, Johnston L, Forsayeth J, et al. Pharmacokinetics and bioactivity of glial cell line-derived factor (GDNF) and neurturin (NTN) infused into the rat brain. Neuropharmacology 2010;58:1114-21.
52. Tatarewicz SM, Wei X, Gupta S, et al. Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputaminal infusion. J Clin Immunol 2007;27:620-7.
53. Hovland Jr DN, Boyd RB, Butt MT, et al. Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF in rhesus monkeys. Toxicol Pathol 2007;35:1013-29.
54. During MJ, Kaplitt MG, Stern MB, et al. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum Gene Ther 2001;12:1589-91.
55. Luo J, Kaplitt MG, Fitzsimons HL, et al. Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 2002;298:425-9. (Pubitemid 35176353)
56. Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007;369:2097-105. (Pubitemid 46935946)
57. Herzog CD, Brown L, Gammon D, et al. Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease. Neurosurgery 2009;64:602-12 discussion 12-3.
58. Kotzbauer PT, Lampe PA, Heuckeroth RO, et al. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 1996;384:467-70. (Pubitemid 26414664)
59. Herzog CD, Dass B, Holden JE, et al. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord 2007;22:1124-32. (Pubitemid 47067222)
60. Oiwa Y, Yoshimura R, Nakai K, et al. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease. Brain Res 2002;947:271-83.
61. William JM, Raymond TB, Joao S, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010;9:1164-72.
62. White EA, Bienemann AS, Sena-Esteves M, et al. Evaluation and optimisation of the administration of recombinant adeno-associated viral vectors (serotypes 2/1, 2/2, 2/rh8, 2/9 and 2/rh10) by convection-enhanced delivery to the striatum. Hum Gene Ther 2011;22:237-51.